Treatment of Limited Cutaneous Systemic Sclerosis with Raynaud's Phenomenon

This protocol addresses Raynaud's phenomenon occurring in the setting of limited cutaneous systemic sclerosis (lcSSc) — a recognised vascular complication that warrants a specific, structured first-line management approach.

Current evidence supports first-line pharmacological treatment with a dihydropyridine-type calcium antagonist. The specific agent, formulation, and full clinical decision pathway are detailed in the complete protocol.

Full regimen, agent selection, and escalation criteria are in the structured protocol below.